18h
MedPage Today on MSNClotting Risk Worse Than Expected in Protein S-Deficient PatientsCarriers of these high-risk variants had total protein S levels that were about half of normal. Less severe gene variants ...
Over 90 nutritionists have hit back at Ozempic maker Novo Nordisk's project to update the Nova classification for ...
21h
GlobalData on MSNNovo Nordisk and AI-driven Gensaic enter into $354m cardiometabolic dealNovo Nordisk has signed a deal with AI-driven protein design company Gensaic to develop tissue-targeted therapies for ...
21h
GlobalData on MSNNovo Holdings and TA Associates back BiocompositesNovo Holdings’ investment alongside Biocomposites’ existing shareholder, TA Associates, will help the company scale its ...
Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing ...
Stifel Nicolaus cut shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a hold rating in a report issued ...
It's the second year in a row that Lilly has used the Oscars as a platform to drive home a message about GLP-1-based obesity ...
During a hearing, representatives for the Newsom administration said they could not provide a timeline for when ...
CAPE TOWN - As the globe observes World Obesity Day. South Africa has come out as the African country with the highest number ...
California made a big bet on producing its own insulin. There’s no ‘date certain’ for delivery
California made a bold announcement that it would manufacture a state-branded, low-cost insulin. It still is not here.
The portfolio was launched 12-1/2 years ago, in August 2012. It had an initial value of $10,000 and a target annual growth rate of 12 per cent. The portfolio is 100 per cent exposure to the equity ...
Could taking tiny fractions of the normal prescribed dose of a medication offer a brilliant way to benefit from the drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results